A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Active Not Recruiting
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: AMCR Institute, Escondido, California +4 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Active Not Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: San Fernando Valley Health Institute, Canoga Park, California +9 locations
Conditions: Type 2 Diabetes
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Active Not Recruiting
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the sc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California +1 locations
Conditions: Healthy, Obese, Overweight, Obesity